BRPI0407181A - Formulação farmacêutica - Google Patents

Formulação farmacêutica

Info

Publication number
BRPI0407181A
BRPI0407181A BR0407181-6A BRPI0407181A BRPI0407181A BR PI0407181 A BRPI0407181 A BR PI0407181A BR PI0407181 A BRPI0407181 A BR PI0407181A BR PI0407181 A BRPI0407181 A BR PI0407181A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
pharmaceutical
preparing
processes
active ingredients
Prior art date
Application number
BR0407181-6A
Other languages
English (en)
Inventor
Rama Ali Shmeis-Ziadeh
James Kowalski
Steven L Krill
Lakshman Jayath Parthiban
Zeren Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0407181A publication Critical patent/BRPI0407181A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO FARMACêUTICA". A presente invenção refere-se a processos para preparar e formar dispersões sólidas de ingredientes ativos farmacêuticos.
BR0407181-6A 2003-02-03 2004-02-02 Formulação farmacêutica BRPI0407181A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44460203P 2003-02-03 2003-02-03
ES2004000925 2004-02-02

Publications (1)

Publication Number Publication Date
BRPI0407181A true BRPI0407181A (pt) 2006-02-07

Family

ID=32850894

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407181-6A BRPI0407181A (pt) 2003-02-03 2004-02-02 Formulação farmacêutica

Country Status (7)

Country Link
US (2) US8486447B2 (pt)
EP (1) EP1594468A2 (pt)
JP (1) JP4783278B2 (pt)
CN (2) CN100594023C (pt)
BR (1) BRPI0407181A (pt)
CA (1) CA2509958A1 (pt)
WO (1) WO2004069138A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CN101384250A (zh) * 2005-11-09 2009-03-11 诺瓦提斯公司 利用临时增塑剂制备药物组合物的方法
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
CA2990445C (en) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
CA2702935A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
CN101618012B (zh) * 2009-07-10 2012-07-04 东华大学 一种难溶性药物固体分散体制备方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
PH12013500655A1 (en) * 2010-10-14 2016-06-29 Abbott Gmbh & Co Kg Curcuminoid solid dispersion formulation
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN103462899B (zh) * 2013-05-20 2016-06-01 浙江鼎辉医药科技有限公司 一种五味子乙素固体分散体及其制备方法和制剂
US11510986B2 (en) * 2016-05-13 2022-11-29 Merck Patent Gmbh Hot melt extrusion composition using direct compressible excipient as plasticizer
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN115397390A (zh) * 2021-03-22 2022-11-25 太阳生物公司 包含聚乙二醇衍生物的用于缓解口腔干燥的口腔冲洗组合物
WO2022203316A1 (ko) * 2021-03-22 2022-09-29 선바이오(주) 폴리에틸렌 글리콜 유도체를 유효성분으로 포함하는 구강건조증 완화용 구강린스 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3024416C2 (de) 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
JPS5879915A (ja) 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4649042A (en) * 1984-05-31 1987-03-10 Eli Lilly And Company Rumen delivery device
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
US5072379A (en) 1989-05-26 1991-12-10 The United States Of America As Represented By The Adminstrator Of The National Aeronautics And Space Administration Network of dedicated processors for finding lowest-cost map path
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5411737A (en) * 1991-10-15 1995-05-02 Merck & Co., Inc. Slow release syneresing polymeric drug delivery device
JPH05139974A (ja) * 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
WO1993011749A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company A process for the preparation of a solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
ES2086229T3 (es) 1992-05-22 1996-06-16 Goedecke Ag Procedimiento para la obtencion de preparados medicinales de accion retardada.
GB2273874A (en) * 1992-12-31 1994-07-06 Pertti Olavi Toermaelae Preparation of pharmaceuticals in a polymer matrix
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
DE4418837A1 (de) 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
DE19531684A1 (de) 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
DE19536394A1 (de) 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
EA001219B1 (ru) * 1996-05-20 2000-12-25 Жансен Фармасетика Н.В. Антигрибковые композиции с улучшенной биологической доступностью
DE19809242A1 (de) 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
WO2002024168A1 (fr) 2000-09-25 2002-03-28 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide medicinale

Also Published As

Publication number Publication date
US20060269608A1 (en) 2006-11-30
CA2509958A1 (en) 2004-08-19
WO2004069138A2 (en) 2004-08-19
CN101091695B (zh) 2011-01-19
CN1747720A (zh) 2006-03-15
US20100179182A1 (en) 2010-07-15
CN101091695A (zh) 2007-12-26
CN100594023C (zh) 2010-03-17
EP1594468A2 (en) 2005-11-16
JP2006516586A (ja) 2006-07-06
JP4783278B2 (ja) 2011-09-28
WO2004069138A3 (en) 2005-01-06
US8486447B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
BRPI0407181A (pt) Formulação farmacêutica
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
MXPA05002814A (es) Formulacion para agentes lipofilicos.
UA96449C2 (en) Stable laquinimod preparations
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
IT1320176B1 (it) Dispersioni solide di principi attivi nitrati.
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
MY143795A (en) Tetrahydropyridoindole derivatives
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
BRPI0414858A (pt) métodos para preparação de corpos de óleo compreendendo ingredientes ativos
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
WO2005065639A3 (en) Novel pharmaceutical compositions
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
DE60225844D1 (de) Micelle-zusammensetzungen enthaltend pegylierten phospholipide und einen photosensibilisator
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EP1741430A4 (en) MEANS FOR THE TREATMENT OF PSYCHONEUROTIC DISEASES
WO2007044574A3 (en) Pharmaceutical compositions, methods of preparation thereof, and methods of treatment

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.